If you want to know who really controls ResMed Inc. (NYSE:RMD), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

Analysts estimate that ResMed will report an earnings per share (EPS) of $2.71. The announcement from ResMed is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

Shares of ResMed Inc. RMD rallied 1.72% to $271.63 Friday, on what proved to be an all-around great trading session for the ...

By Siddhi Mahatole Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.86, with a ...

ResMed’s fourth quarter performance drew a positive market reaction, with management attributing the outperformance to strong global demand for its masks and devices, as well as continued growth in ...

Air Voel, a fast-growing Canadian provider of sleep therapy and respiratory care equipment, has announced the expansion ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...